These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 3091692)

  • 1. Amelioration of acute graft vs host disease due to minor histocompatibility antigens by in vivo administration of anti-interleukin 2 receptor antibody.
    Ferrara JL; Marion A; McIntyre JF; Murphy GF; Burakoff SJ
    J Immunol; 1986 Sep; 137(6):1874-7. PubMed ID: 3091692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute cutaneous graft-versus-host disease to minor histocompatibility antigens in a murine model. Evidence that large granular lymphocytes are effector cells in the immune response.
    Guillén FJ; Ferrara J; Hancock WW; Messadi D; Fonferko E; Burakoff SJ; Murphy GF
    Lab Invest; 1986 Jul; 55(1):35-42. PubMed ID: 3523039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of lethal, minor-determinate graft-host disease in mice by the in vivo administration of anti-asialo GM1.
    Charley MR; Mikhael A; Bennett M; Gilliam JN; Sontheimer RD
    J Immunol; 1983 Nov; 131(5):2101-3. PubMed ID: 6355291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolongation of murine skin allograft survival by immunologic manipulation with anti-interleukin 2 receptor antibody.
    Granstein RD; Goulston C; Gaulton GN
    J Immunol; 1986 Feb; 136(3):898-902. PubMed ID: 3079802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo or in vitro anti-CD3 epsilon chain monoclonal antibody therapy for the prevention of lethal murine graft-versus-host disease across the major histocompatibility barrier in mice.
    Blazar BR; Taylor PA; Vallera DA
    J Immunol; 1994 Apr; 152(7):3665-74. PubMed ID: 8144942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amelioration of acute graft-versus-host disease and re-establishment of tolerance by short-term treatment with an anti-TCR antibody.
    Maeda T; Eto M; Lin T; Nishimura Y; Kong YY; Nomoto K; Nomoto K
    J Immunol; 1994 Nov; 153(9):4311-20. PubMed ID: 7930630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional T cell deficits after bone marrow transplantation across minor histocompatibility barriers: effects of graft-vs-host disease on precursor frequency of reactive cells.
    Ferrara JL; Daley JP; Burakoff SJ; Miller RA
    J Immunol; 1987 Jun; 138(11):3598-603. PubMed ID: 3108369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. L3T4-positive T cells participate in the induction of graft-vs-host disease in response to minor histocompatibility antigens.
    Hamilton BL
    J Immunol; 1987 Oct; 139(8):2511-5. PubMed ID: 3498761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A CD8 DE loop peptide analog prevents graft-versus-host disease in a multiple minor histocompatibility antigen-mismatched bone marrow transplantation model.
    Choksi S; Kim JC; Whitaker-Menezes D; Murphy GF; Friedman TM; Korngold R
    Biol Blood Marrow Transplant; 2004 Oct; 10(10):669-80. PubMed ID: 15389433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specific donor Vbeta-associated CD4 T-cell responses correlate with severe acute graft-versus-host disease directed to multiple minor histocompatibility antigens.
    Jones SC; Friedman TM; Murphy GF; Korngold R
    Biol Blood Marrow Transplant; 2004 Feb; 10(2):91-105. PubMed ID: 14750075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of T cell costimulation by VCAM-1 prevents murine graft-versus-host disease across minor histocompatibility barriers.
    Schlegel PG; Vaysburd M; Chen Y; Butcher EC; Chao NJ
    J Immunol; 1995 Oct; 155(8):3856-65. PubMed ID: 7561092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of lethal graft-versus-host disease by anti-CD137 monoclonal antibody in mice prone to chronic graft-versus-host disease.
    Kim W; Kim J; Jung D; Kim H; Choi HJ; Cho HR; Kwon B
    Biol Blood Marrow Transplant; 2009 Mar; 15(3):306-14. PubMed ID: 19203721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blockade of acute grade IV skin and eye graft-versus-host disease by anti-interleukin-2 receptor monoclonal antibody in genoidentical bone marrow transplantation setting.
    Ozşahin H; Tuchschmid P; Lauener R; Waldvogel K; Nadal D; Seger RA
    Turk J Pediatr; 1998; 40(2):231-5. PubMed ID: 9677728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amelioration of acute graft-versus-host disease by NKG2A engagement on donor T cells.
    Kawamura H; Yagita H; Nisizawa T; Izumi N; Miyaji C; Vance RE; Raulet DH; Okumura K; Abo T
    Eur J Immunol; 2005 Aug; 35(8):2358-66. PubMed ID: 15997467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of steroid-resistant acute graft-versus-host disease with an anti-IL-2-receptor monoclonal antibody (BT 563) in children who received T cell-depleted, partially matched, related bone marrow transplants.
    Herbelin C; Stephan JL; Donadieu J; Le Deist F; Racadot E; Wijdenes J; Fischer A
    Bone Marrow Transplant; 1994 May; 13(5):563-9. PubMed ID: 8054909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T cell subsets involved in lethal graft-versus-host disease directed to immunodominant minor histocompatibility antigens.
    Berger M; Wettstein PJ; Korngold R
    Transplantation; 1994 Apr; 57(7):1095-102. PubMed ID: 7909395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment.
    Drobyski WR; Majewski D; Ozker K; Hanson G
    J Immunol; 1998 Sep; 161(5):2610-9. PubMed ID: 9725263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.
    Jones SC; Murphy GF; Korngold R
    Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-2 reduces graft-versus-host disease and preserves a graft-versus-leukemia effect by selectively inhibiting CD4+ T cell activity.
    Sykes M; Abraham VS; Harty MW; Pearson DA
    J Immunol; 1993 Jan; 150(1):197-205. PubMed ID: 8093257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of exogenous interleukin-10 in a murine model of graft-versus-host disease to minor histocompatibility antigens.
    Krenger W; Snyder K; Smith S; Ferrara JL
    Transplantation; 1994 Dec; 58(11):1251-7. PubMed ID: 7992370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.